Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States
Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures
Objective: In this study, we wish to determine whether medication changes play a major role in the improvements observed after in-patient multimodal intensive neurorehabilitation and…Continuous Subcutaneous Dopaminergic Stimulation: Exploring the impact of Foslevodopa/Foscarbidopa on Gait in Parkinson’s disease.
Objective: The primary objective of this study is to investigate the effect of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (FL/FC) on gait in those with…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease
Objective: This case report aims to highlight the impact of increasing venlafaxine dose on the worsening of dyskinesias and the onset of ocular dyskinesia³ and…Opicapone for OFF Motor Fluctuations in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials
Objective: To evaluate the efficacy of opicapone 50 mg in reducing OFF time and improving motor function in Parkinson’s disease (PD) patients with motor fluctuations.…The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs
Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…Nutrition, Motor And Non-Motor Symptoms Impact On Life’s Quality In Parkinson’s Disease In Second-Line Therapies
Objective: Analyze the nutritional status, motor and non-motor symptoms of patients with Parkinson´s disease (PD) with second-line therapies [levodopa carbidopa intestinal gel (LCIG) and deep…Early Introduction of COMT Inhibitors at Low Levodopa Doses Improves Long-Term Motor Complications in Parkinson’s Disease: A sub-analysis of the REONPARK Study
Objective: This sub-analysis of the REONPARK study aims to identify predictive factors for the greater effectiveness of COMT inhibitors (COMTi) in alleviating motor complications in…
- « Previous Page
- 1
- …
- 359
- 360
- 361
- 362
- 363
- …
- 1942
- Next Page »